May 22, 2019 — Edwards Lifesciences Corp. announced strategic clinical and regulatory milestones for its Edwards Pascal ...
Heart Failure
This heart failure channel offers news and new technology to treat heart failure. This includes for new innovations to treat congestive heart failure (CHF). The channel includes news on HFpEF and HFrEF. Heart failure occurs when the heart is no longer able to pump as much blood as the body requires. This can lead to enlargement of the heart because the muscle works harder to supply blood, but the pumping is ineffective. This may be due to defects in the myocardium, such as an infarct, or due to structural issues such as severe valve regurgitation. The disease is divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or a left ventricular assist device (LVAD).
May 22, 2019
News | Cardiac Resynchronization Therapy Devices (CRT) | Dave Fornell, Editor
May 15, 2019 — A pilot trial has shown His pacing in cardiac resynchronization therapy (CRT) has been shown to ...
May 15, 2019
May 14, 2019 — The U.S. Food and Drug Administration (FDA) has approved the expansion of Abiomed’s Impella 5.0 and ...
May 14, 2019Sponsored Content
Blog | Artificial Intelligence
New research shows superiority of Ultromics’ AI in predicting cardiac-related death As the use of artificial ...
October 10, 2022
May 6, 2019 — The U.S. Food and Drug Administration (FDA) approved tafamidis meglumine (Vyndaqel) and tafamidis ...
May 06, 2019
Feature | Heart Failure | Will Clifton, M.D.
The heart and kidneys are inextricably linked through a diverse web of hemodynamic, neural and hormonal mechanisms. As ...
April 29, 2019
April 19, 2019 – Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated that the recently ...
April 19, 2019
March 29, 2019 — The cardiovascular benefits of the diabetes drug dapagliflozin extend across a wide spectrum of ...
March 29, 2019![New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/valsartan (Entresto) continued to deliver reductions in the heart failure biomarker N-terminal pro–B-type natriuretic peptide (NT-proBNP), an established biomarker for heart failure severity and prognosis.[1] The data was presented as a late-breaker at the American College of Cardiology (ACC) 2019 Annual Scientific Session in March.](/sites/default/files/styles/content_feed_medium/public/Entresto_bottles.jpg?itok=sp56E5GI)
March 27, 2019 —New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril ...
March 27, 2019
March 26, 2019 — A toilet seat-based cardiovascular monitoring system created by a team of Rochester Institute of ...
March 26, 2019
March 22, 2019 — Severely ill patients with advanced heart failure who received the HeartMate 3 left ventricular assist ...
March 22, 2019
March 21, 2019 — Clinicians should use echocardiography when determining whether patients with heart failure and a ...
March 21, 2019
March 21, 2019 — The U.S. Food and Drug Administration (FDA) approved Impulse Dynamics’ Optimizer Smart system for ...
March 21, 2019
The American College of Cardiology (ACC) released a list of the latest practice-changing presentations at the ACC.19 ...
March 19, 2019
March 15, 2019 – Biotronik announced U.S. Food and Drug Administration (FDA) approval of the Acticor and Rivacor high ...
March 15, 2019
Feature | Heart Valve Technology | Jeff Zagoudis, Associate Editor
March 14, 2019 — The U.S. Food and Drug Administration (FDA) approved the MitraClip heart valve repair device for ...
March 14, 2019© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now